| CARVIEW |
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases & Vaccines
- Oncology & Hematology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS
- Real World & Healthcare Data
- Health Data Apps & AI
- Analytics Research Accelerator
- Expert Ecosystem
- AI Patient & HCP Profiling- Commercial
- AI Patient & Provider Profiling- Med Affairs
- AI Patient & HCP Profiling- Healthcare
- Natural Language Processing
- Market Access Insights
- Direct-to-Patient Research
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI®
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Global Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREIQVIA Careers
Featured Careers
Stay Connected
WE'RE HIRING
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESAbout IQVIA Indonesia
Driving Healthcare Performance in Indonesia
Established in 1990, IQVIA Indonesia offers a broad range of clinical and commercial services and solutions. Our commercial services started with market data and expanded into market research. We recently launched new audits aligned to current market dynamics.
We offer a full range of development services, including clinical monitoring, patient recruitment, site management, quality management and medical services. Our staff includes experienced clinical trial monitors from a range of backgrounds, including medical doctors, pharmacists and bio-medical scientists.
Indonesia Healthcare Outlook
Since the launch of Indonesia's Universal Health Coverage (UHC) program in 2014, about 180 million people have enrolled - almost 70 percent of the country's total population of 259 million. By 2019, UHC enrollment is forecast to reach 100 percent. Indonesia’s private insurance penetration is estimated at 8 percent, or 20 million people. UHC could drive the demand for inpatient and outpatient services at public hospitals and also among participating private hospitals as more patients have access to healthcare.
Indonesia’s growing economy is expanding the middle class. Both rising incomes and the UHC program are expected to accelerate private sector investment in healthcare.
Primary health care is the front line of the UHC program administered by the Ministry of Health. Patient volume is expected to increase significantly between now and 2019. Despite improvements at government-owned hospitals, the increased volume is expected to result in longer waits for patients. Those with private insurance or the ability to pay out-of-pocket can expect shorter wait periods; those with the need for specialist doctors will likely go to private hospitals.
Biopharmaceutical Market Overview
The generic segment remains the most attractive. Local and multinational drug manufacturers are expecting consumption to continue to increase as a result of UHC-driven demand from government-run and participating private hospitals. Indonesia accounts for the highest proportion of ASEAN over-the-counter (OTC) medicine sales, 40 percent, indicating the propensity of domestic consumers for self-medication. OTC manufacturers can expect growing demand during the medium to long terms.
Middle-class Indonesian consumers increasingly prefer branded generics to lower-cost, unbranded drugs, creating opportunities for generic manufacturers and importers. With the increase access to healthcare through UHC and economic improvement, people are likely to move away from self-treatment to seek treatment in clinic and hospitals.
To meet the growing demand, the Indonesian government has been pushing for self-sufficient drug production and opening the pharmaceutical industry to foreign investment. The Indonesian government intends to address major health condition by obtaining more affordable drugs in area of oncology, cardiovascular, diabetes and infectious disease by way of using biosimilar product and vaccine. Improving clinical trial capability is one way to answer the country’s need for more innovative healthcare solutions to address these needs.
Regulatory Environment for Clinical Development
The government is supporting efforts to transform Indonesia's biopharmaceutical and medical device industry from its focus on manufacturing/production to be more R&D- and innovation-based. Early engagement with local regulatory authorities is essential for success in clinical development programs that include Indonesia.
There are types of research that does not require regulatory authority approval, such as disease or product registry studies; health economic and outcomes research; and local data generation for regulatory and marketing purposes. These types of research are still very much needed in the country to drive public health policies.
Among recent significant regulatory changes are:
- Presidential Instruction No. 6 year 2016 (re-emphasized by the Ministry of Health Decree No. 17 in 2017) provides direction for the biopharma and medical devices to support improvement in health services under UHC.
- Head of National Agency of Drug and Food Control Decree No. 21 (2015) regulating clinical trial conduct for pre- and post-marketing (phase I to IV) studies inclusive of vaccine development guidelines.
- Head of National Agency of Drug and Food Control Decree No. 16 (2015) regulates new drug development and manufacturing by local and foreign research institutions or the pharmaceutical industry.
- Head of National Agency of Drug and Food Control Decree No. 17 (2015) provides guidance for research and development of biosimilars.
Disease Prevalence
Non-communicable diseases (NCDs) account for about two-thirds of all deaths in Indonesia. The four major NCDs are cardiovascular diseases, diabetes, cancers, and chronic respiratory diseases. Significant communicable diseases are tuberculosis, HIV/AIDS, diarrhoea, malaria, pneumonia, hepatitis and tropical diseases such as rabies, leprosy, filariasis, leptospirosis, anthrax, yaws. All these remain on the government’s strategic health agenda.
Commercial Solutions
- Information: Sales Audit and Prescription Audit
- Primary Market Research: Market Assessment, Brand Tracking and Customer Satisfaction
- Analytics: Segmentation & Targeting, Sales Force Size & Structure, Territory Alignment and Incentive Compensation
Clinical Research Experience & Services
We have strong experience in infectious diseases, respiratory, cardiovascular and metabolic diseases, psychiatry, and rheumatology. Our experiences range from early phase development to observational and Phase 4 studies, including Real-World Insights, and have specialized offerings for Investigator-Initiated Trials (IIT).